Global Encephalitis Vaccines Market Size, Share, and COVID-19 Impact Analysis, By Vaccine Type (Mouse Brain-Derived Inactivated Vaccine, Cell Culture-Derived Inactivated Vaccine, Cell Culture-Derived Live Attenuated Vaccine), Indication Type (Japanese Encephalitis, Tick-Borne Encephalitis, Rabies Encephalitis), By End-User (Child and Adult), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032Industry: Healthcare
Global Encephalitis Vaccines Market Insights Forecasts to 2032
- The Global Encephalitis Vaccines Market Size was valued at USD 19.36 Billion in 2022.
- The Market is growing at a CAGR of 8.1 % from 2022 to 2032.
- The Worldwide Encephalitis Vaccines Market size is expected to reach USD 42.2 Billion by 2032.
- Europe is expected to grow the fastest during the forecast period.
Get more details on this report -
The Global Encephalitis Vaccines Market Size is expected to reach USD 42.2 Billion by 2032, at a CAGR of 8.1 % during the forecast period 2022 to 2032.
Encephalitis virus is a mosquito-borne Flavivirus that spreads from mosquitos to amplifying vertebrate hosts like pigs and wading birds via an enzootic cycle. It is easily preventable with immunizations. In Asia-Pacific, it is the most common cause of encephalitis. The encephalitis virus is easily spread to people by an infected mosquito bite and is most common in rural agricultural settings. The danger of contracting the encephalitis virus is low; nonetheless, the incidence rate varies according to duration, season, location, and activities. The high mortality and morbidity rate caused by the encephalitis virus occurrence is a crucial element contributing to the market's growth. Furthermore, increased government initiatives for vaccination programs are driving the industry. According to the World Health Organization, 37 human cases of Japanese encephalitis (25 laboratory-confirmed cases and 12 probable cases) had been identified in four Australian states as of April 28, 2022.
This research report categorizes the global encephalitis vaccines market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global encephalitis vaccines market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global encephalitis vaccines market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.
Global Encephalitis Vaccines Market Report Coverage
|Market Size in 2022:||USD 19.36 Billion|
|Forecast Period 2022-2032 CAGR:||8.1%|
|2032 Value Projection:||USD 42.2 Billion|
|Historical Data for:||2018-2021|
|No. of Pages:||200|
|Tables, Charts & Figures:||100|
|Segments covered:||By Vaccine Type, By End-User, By Region|
|Companies Covered:||Liaoning Cheng Bio Co, Wuhan Institute of Biological Products, Valneva, Tiantan Biological Products, Sanofi Pasteur, Chengdu Institute of Biological Products, GlaxoSmithKline plc, Lanzhou Institute of Biological Products, Zhejiang Tianyuan Bio-Pharmaceutical|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
The rising prevalence of encephalitis, including viral infections such as Japanese encephalitis, tick-borne encephalitis, and others, is a significant driving factor. In addition, the occurrence of encephalitis cases in various regions creates a need for effective preventive measures such as vaccines. Also, governments across the globe, especially in regions with high encephalitis incidence, are actively promoting vaccination programs. They invest in public health campaigns and provide funding for immunization, which increases the demand for encephalitis vaccines. Also, Boosting the number of programs and efforts for improving awareness regarding the benefits of these vaccines will further serve to propel market expansion. Moreover, Encephalitis vaccines are often included in expanded immunization programs by governments and international organizations. Moreover, the inclusion of these vaccines in routine immunization schedules increases their uptake and demand. In addition, Investments in research and development by pharmaceutical companies and government agencies contribute to the development of new and improved encephalitis vaccines. These investments drive innovation and further expansion of the market.
Encephalitis vaccines can be relatively expensive, particularly in developing countries with limited healthcare budgets. The high cost of vaccines can hinder their affordability and accessibility, especially for low-income populations, thereby limiting their market penetration. Moreover, safety concerns or adverse events associated with vaccines can raise public apprehension and negatively impact vaccine acceptance. While encephalitis vaccines are generally considered safe, any reports of adverse effects can create hesitancy and affect market demand. Furthermore, limited healthcare infrastructure in certain regions, particularly in rural and underserved areas, can restricts the distribution, storage, and administration of encephalitis vaccines. Insufficient healthcare facilities and trained personnel can pose challenges to vaccine delivery and utilization.
- In 2022, the Cell culture-derived inactivated vaccines segment is influencing the market with the largest market share over the forecast period.
Based on the vaccine type, the global encephalitis vaccines market is divided into different segments such as, mouse brain-derived inactivated vaccine, cell culture-derived Inactivated Vaccine, Cell Culture-Derived Live Attenuated Vaccine. Among these segments, Cell culture-derived inactivated vaccines dominate the market growth. Cell culture-derived inactivated vaccines have gained prominence due to their effectiveness and safety. These vaccines are produced by growing the virus in cell cultures, inactivating it, and then using it to stimulate an immune response. This manufacturing process eliminates the need for using mouse brain tissue, which was previously used in mouse brain-derived inactivated vaccines.
- In 2022, the Japanese Encephalitis (JE) vaccine segment is dominating the largest market growth during the forecast period.
On the basis of indication type, the global encephalitis vaccines market is segmented into different segments such as Japanese Encephalitis, Tick-Borne Encephalitis, Rabies Encephalitis. The Japanese encephalitis (JE) vaccine segment is expected to grow at an important pace over the forecast period. Japanese Encephalitis is a viral infection transmitted by mosquitoes, primarily prevalent in Asia. It is a leading cause of viral encephalitis in many countries in the region. Given the high incidence and impact of Japanese Encephalitis, the demand for JE vaccines has been significant, particularly in countries where the disease is endemic. In addition, government initiatives for JE vaccine programs further stimulate the segment. The governments of India have developed national immunization plans that are massively vaccinated. For example, in July 2022, the chief medical officer of Nainital initiated a widespread vaccination drive in private and government schools for children aged 1 to 15 years to be inoculated against Japanese Encephalitis.
Regional Segment Analysis of the global encephalitis vaccines market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
Asia-Pacific Dominate the Encephalitis Vaccines Market during the Forecast Period
Get more details on this report -
The Asia pacific market is anticipated to experience exponential growth over the forecast period. Japanese encephalitis is widespread in Asian countries. As claimed by the updates from European Centre for Disease Prevention and Control in March 2022, the Japanese Encephalitis virus can be found throughout Asia and Oceania, from Japan to India, Pakistan, and Australia. Outbreaks are unpredictable, chaotic and confined by geography and time. Approximately 30,000 to 50,000 cases are registered every year, and the virus is a major cause of viral encephalitis in Asia. As a result, the growing incidence of encephalitis in the region has had a positive impact on market growth over the forecast horizon. Moreover, growing investment in the R&D sector, entry of new vaccine manufacturers in countries like India and China, an increasing number of travelers in the region, and medical tourism is propelling the market growth in the region.
Europe is the second largest market for encephalitis vaccines, due to the high prevalence of encephalitis and the availability of new vaccines.
The report offers the appropriate analysis of the key organizations/companies involved within the global microgrid market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Liaoning Cheng Bio Co
- Wuhan Institute of Biological Products
- Tiantan Biological Products
- Sanofi Pasteur
- Chengdu Institute of Biological Products
- GlaxoSmithKline plc
- Lanzhou Institute of Biological Products
- Zhejiang Tianyuan Bio-Pharmaceutical
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In September 2022, NSW expanded free access to the Japanese encephalitis (JE) vaccine to residents living in affected regional areas to protect those most at risk.
- In September 2021, Valneva SE stated that the United States Department of Defense (DoD) has exercised the first option under a contract signed in September 2020 to purchase further supplies of its Japanese encephalitis (JE) vaccine IXIARO.
This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Encephalitis Vaccines market based on the below-mentioned segments:
Global Encephalitis Vaccines market, By Vaccine Type
- Mouse Brain-Derived Inactivated Vaccine
- Cell Culture-Derived Inactivated Vaccine
- Cell Culture-Derived Live Attenuated Vaccine
Global Encephalitis Vaccines market, By Indication Type
- Japanese Encephalitis
- Tick-Borne Encephalitis
- Rabies Encephalitis
Global Encephalitis Vaccines market, By End Users
Encephalitis Vaccines market, By Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
Need help to buy this report?